CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study
Authors
Jakub Trefler (ORCID: https://orcid.org/0009-0003-3912-3518)
Janusz Jaworski (ORCID: https://orcid.org/0000-0002-2664-1012)
HyunJin Lee (ORCID: https://orcid.org/0000-0002-2112-354X)
CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study
Jakub Trefler, Janusz Jaworski, HyunJin Lee, Eunjin Choi et al.
Journal
Dermatology and Therapy
Topics
Biosimilars and Bioanalytical Methods
article
CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study
Jakub Trefler, Janusz Jaworski, HyunJin Lee, Eunjin Choi, Stefan Daniluk, Mark Lebwohl, Witold Owczarek, JungBin Cha, Mariusz Sikora, Marek Krogulec, Anna Dudek, Paweł Brzewski, David M. Pariser, S.J. Lee, Wojciech Baran, John Koo, JeeHye Suh, SungHyun Kim
article en
Abstract
No abstract available for this paper.
Publication Tag
Dermatology and TherapyVol. 15(5)
Institutions
National Academy of Medicine (US), Royal College of Emergency Medicine (GB), Eastern Virginia Medical School (US), Wroclaw Medical University (PL), Meditest (PL), NOK Corporation (Japan) (JP), Virginia Clinical Research (US), University of California San Francisco Medical Center (US), Centrum Medyczne iMed24 (PL), Euro-Centrum (PL), National Institute of Geriatrics, Rheumatology and Rehabilitation (PL), Międzyleski Szpital Specjalistyczny w Warszawie (PL), Krakow Cardiovascular Research Institute (PL), Celltrion (South Korea) (KR), Icahn School of Medicine at Mount Sinai (US)